Investing in Cogent Biosciences, Inc. (COGT)  ➔  Intrinsic value

Prev. close$9.27 
ModelValueUpside
Chepakovich$6.58-29%
Graham-Dodd$0.00-100%
Graham$70.69+663%
Previous Close$9.27  
Valuation MethodValuePotential 
Chepakovich Model$6.58-29%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$70.69+663%recalculate

Latest news

Company description

Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ‘bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.